BridgeBio

BridgeBio is a United States-based biotechnology, healthcare, life sciences, and pharmaceutical company founded in 2015. Their slogan, "Hope Through Rigorous Science," encapsulates their mission to find, develop, and deliver breakthrough medicines for genetic diseases. The company addresses the unmet needs of millions afflicted with genetic diseases, striving to bridge the gap between scientific possibility and business case, and between patients and hope. BridgeBio's commitment extends beyond drug development; they are dedicated to cultivating leaders in the field of genetic medicine. Their last investment of $250.00M in post-IPO equity at 05 March 2024 signifies investor confidence and an infusion of capital to drive their mission forward. Currently, there is no specific information available about the last investment's investors. The company's approach is to create an entrepreneurial engine capable of rapidly delivering life-changing medicines. They seek individuals driven by passion and a commitment to overcoming adversity with novel solutions. BridgeBio's unique focus on genetic diseases and their recent substantial investment positions them as a significant player in the biotech and pharmaceutical industries.